Eiger BioPharmaceuticals adds two to senior management team

Jim Welch joins as Chief Financial Officer and Jim Shaffer as Chief Business Officer

Eiger BioPharmaceuticals, a privately owned Californian biopharmaceutical company developing therapies for orphan diseases, has appointed James Welch as Chief Financial Officer and James Shaffer as Chief Business Officer.

Prior to joining Eiger, Welch was Chief Financial Officer and Secretary of Virobay Incorporated. He was also Chief Financial Officer of Acelrx Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Cerimon Pharmaceuticals, Chief Financial Officer and Corporate Secretary at Rigel Pharmaceuticals, and earlier in his career was Chief Financial Officer of Biocircuits diagnostics.

Shaffer was previously Vice President and Chief Commercial Officer at Halozyme Therapeutics. He was also Executive Vice President and Chief Commercial Officer at Clinical Data, which was acquired by Forest Labs. He has also worked at New River Pharmaceuticals as Vice President of Commercial Operations, in addition to Prestwick Pharmaceuticals, InterMune, GlaxoSmithKline and Merck.

You may also like

Pharmaceutical

Eiger Bio strengthens senior management team

By hiring Debra Odink as Senior Vice President of Technical Operations
Finance

Eiger BioPharmaceuticals closes merger with Celladon

The US firm is developing a clinical stage pipeline of orphan disease programmes
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Can creative carriers deliver the goods?

There are many reasons why conventional drug delivery technologies may not be effective and a more creative approach is required to convey the active ingredient to its destination. Dr Sarah Houlton looks at the more promising technologies in development
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Distribution

Tower Cold Chain’ industry-first shipping container design

The pyramidal solution allows pharmaceuticals to be shipped at a consistent temperature between -60°C to above +20°C for up to 96 hours
Manufacturing

Memel Biotech and Therabest collaborate to develop exosome-based cell therapies

The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Subscribe now